GH Research initiated with a Buy at Needham

Needham initiated coverage of GH Research (GHRS) with a Buy rating and $19 price target The company’s GH001 demonstrated “impressive efficacy” in Phase 2 and “potentially game-changing” 73% remission rate at six months with re-treatments, the analyst tells investors in a research note. Needham estimates GH001 could be a significant opportunity with sales of $1.9B in U.S. by 2035.